Skip to main content

Table 5 Distribution of study participants according medical/medication history, Women Hospital-Hamad Medical Corporation, 2018

From: Risk profile of Qatari women treated for infertility in a tertiary hospital: a case-control study

Medical/ Medication history Cases Cases Controls p value
Primary Infertility
n = 43 (%)
Secondary Infertility
n = 93 (%)
Infertility Total
n = 136 (%)
n = 272 (%)
Hypothyroidism: 0.025*
 No 35 (81.4) 75 (80.6) 110 (80.9) 242 (89.0)
 Yes 8 (18.6) 18 (19.4) 26 (19.1) 30 (11.0)
Hyperprolactinemia: 0.001*
 No 34 (79.1) 78 (83.9) 112 (82.4) 255 (93.8)
  Yes 9 (20.9) 15 (16.1) 24 (17.6) 17 (6.2)
Depression and/or other psychological disorders: 0.002*
 No 40 (93.0) 88 (94.6) 128 (94.1) 270 (99.3)
  Yes 3 (7.0) 5 (5.4) 8 (5.9) 2 (0.7)
Polycystic ovarian syndrome: 0.001*
 No 21 (48.8) 43 (46.2) 64 (47.1) 220 (80.9)
 Yes 22 (51.2) 50 (53.8) 72 (52.9) 52 (19.1)
Fibroid uterus: 0.026*
 No 37 (86.0) 86 (92.5) 123 (90.4) 261 (96.0)
  Yes 6 (14.0) 7 (7.5) 13 (19.6) 11 (4.0)
Appendectomy 0.035*
  No 41 (95.3) 84 (94.3) 125 (91.9) 263 (96.7)
 Yes 2 (4.7) 9 (9.7) 11 (8.3) 9 (3.3)
Prolonged steroid: 0.050*
 No 42 (97.7) 84 (90.3) 126(92.6) 267 (98.2)
  Yes 1 (2.3) 9 (9.7) 10 (7.4) 5 (1.8)
Hormonal therapy: 0.001*
 No 15 (34.9) 19 (20.4) 34 (25.0) 260 (95.6)
 Yes 28 (65.1) 74 (79.6) 102(75.0) 12 (4.4)
Prolonged high dose of NSAID: 0.001*
 No 40 (93.0) 78 (83.9) 118(86.8) 261 (96.0)
 Yes 3 (7.0) 15 (16.1) 18 (13.2) 11 (4.0)
Anti-obesity
(Xenical®,Meridia®):
0.001*
 No 42 (97.7) 81 (87.1) 123(90.4) 267 (98.2)
 Yes 1 (2.3) 12 (12.9) 13 (9.6) 5 (1.8)
  1. * p < 0.05
  2. NSAID Non-Steroidal Anti Inflammatory Drugs
  3. Xenical® is the trade name for Orlistat, Meridia® is the trade name for Sibutranine